DE602005027747D1 - Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen - Google Patents

Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen

Info

Publication number
DE602005027747D1
DE602005027747D1 DE602005027747T DE602005027747T DE602005027747D1 DE 602005027747 D1 DE602005027747 D1 DE 602005027747D1 DE 602005027747 T DE602005027747 T DE 602005027747T DE 602005027747 T DE602005027747 T DE 602005027747T DE 602005027747 D1 DE602005027747 D1 DE 602005027747D1
Authority
DE
Germany
Prior art keywords
gensilencing
hbv
hcv sequences
hcv
conserved hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005027747T
Other languages
German (de)
English (en)
Inventor
Catherine Pachuk
Chandrasekhar Satishchandran
Vincent Zurawski Jr
Liat Mintz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of DE602005027747D1 publication Critical patent/DE602005027747D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Silicon Polymers (AREA)
DE602005027747T 2004-12-22 2005-12-20 Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen Expired - Lifetime DE602005027747D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63829404P 2004-12-22 2004-12-22
PCT/US2005/046162 WO2006069064A2 (en) 2004-12-22 2005-12-20 Conserved hbv and hcv sequences useful for gene silencing

Publications (1)

Publication Number Publication Date
DE602005027747D1 true DE602005027747D1 (de) 2011-06-09

Family

ID=36602266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027747T Expired - Lifetime DE602005027747D1 (de) 2004-12-22 2005-12-20 Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen

Country Status (7)

Country Link
EP (2) EP1833967B1 (enExample)
JP (3) JP2008525029A (enExample)
AT (1) ATE507293T1 (enExample)
AU (1) AU2005319306B9 (enExample)
CA (1) CA2592099A1 (enExample)
DE (1) DE602005027747D1 (enExample)
WO (1) WO2006069064A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575327B2 (en) * 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP2325314B1 (en) * 2004-09-24 2014-08-20 Alnylam Pharmaceuticals, Inc. Targeting opposite strand replication intermediates of single-stranded viruses by RNAI
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP3505528B1 (en) 2011-04-21 2020-11-25 Ionis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
WO2013119793A1 (en) * 2012-02-07 2013-08-15 University Of Kansas Chemiluminescent nanoparticles and uses thereof
WO2013159109A1 (en) * 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
KR102479178B1 (ko) * 2012-12-06 2022-12-19 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
ES2895977T3 (es) * 2013-11-28 2022-02-23 Bavarian Nordic As Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
SG11201708679YA (en) * 2015-05-06 2017-11-29 Benitec Biopharma Ltd Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
EP3452595A4 (en) 2016-05-05 2020-02-19 Benitec Biopharma Limited REAGENTS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF
KR20190076050A (ko) * 2016-11-11 2019-07-01 얀센 바이오파마, 인크. Hbv cccdna용 올리고뉴클레오티드 표적화 방법
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
EP3837366A1 (en) 2018-08-13 2021-06-23 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
EP0732397A3 (en) 1988-02-05 1996-10-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995027788A1 (en) * 1994-04-11 1995-10-19 Dainabot Co., Ltd. Polypeptide derived from variant hepatitis b virus, gene encoding the same, and related dna
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5874565A (en) 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5843770A (en) * 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
CA2306733A1 (en) 1997-10-28 1999-05-06 American Home Products Corporation Compositions and methods for delivery of genetic material
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20010041902A (ko) 1998-03-16 2001-05-25 데이비드 엠 모이어 포유류의 피부 내의 셀룰라이트를 감소시키는 방법
BR0009884A (pt) 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
WO2001038498A2 (en) * 1999-11-24 2001-05-31 Pharmasset, Ltd. A new genotype of hepatitis b virus
JP2003515327A (ja) * 1999-12-03 2003-05-07 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｈｂｖ配列
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2002072763A2 (en) * 2001-03-09 2002-09-19 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
DE10163098B4 (de) * 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2003093775A2 (en) 2002-05-03 2003-11-13 Harman International Industries, Incorporated Sound detection and localization system
WO2004011624A2 (en) * 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
US7303906B2 (en) 2002-09-06 2007-12-04 Wisconsin Alumni Research Foundation Competent bacteria
CA2502649A1 (en) 2002-10-18 2004-04-29 Nucleonics Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
AU2003284624B2 (en) * 2002-11-22 2010-06-03 Bio-Think Tank Co. Ltd Method for searching target base sequence of RNA interference, method for designing base sequence of polynucleotide for causing RNA interference, method for producing double-stranded polynucleotide, method for inhibiting gene expression, base sequence processing apparatus, program for running base sequence processing method on computer, recording medium, and base sequence processing system
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004063375A1 (en) * 2003-01-15 2004-07-29 Hans Prydz OPTIMIZING siRNA BY RNAi ANTISENSE
EP1591524A4 (en) * 2003-01-24 2007-12-26 Tokyo Metropolitan Org Med Res OLIGORIBONUCLEOTIDE OR PEPTIDIC NUCLEIC ACID, THE BZW. THE FUNCTION OF THE HEPATITIS C-VIRUS HEMMT
CA2517235A1 (en) 2003-02-27 2004-09-10 Nucleonics Inc. Methods and constructs for evaluation of rnai targets and effector molecules
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
CA3040025C (en) * 2003-06-12 2023-01-10 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
WO2005007877A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Regulatable promoters for synthesis of small hairpin rna
WO2005007875A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Enhanced promoters for synthesis of small hairpin rna
WO2006033756A2 (en) * 2004-08-23 2006-03-30 Nucleonics, Inc. Multiple rna polymerase iii promoter expression constructs
JP5671371B2 (ja) * 2011-03-01 2015-02-18 株式会社山本鉄工所 連続プレス装置
JP2015086965A (ja) 2013-10-31 2015-05-07 株式会社エクセディ フライホイール組立体

Also Published As

Publication number Publication date
EP1833967A2 (en) 2007-09-19
ATE507293T1 (de) 2011-05-15
EP2316942B1 (en) 2021-04-21
EP1833967B1 (en) 2011-04-27
WO2006069064A2 (en) 2006-06-29
EP2316942A1 (en) 2011-05-04
AU2005319306B9 (en) 2012-04-05
AU2005319306B2 (en) 2012-01-12
AU2005319306A1 (en) 2006-06-29
JP2012223202A (ja) 2012-11-15
JP5934310B2 (ja) 2016-06-15
WO2006069064A3 (en) 2007-10-25
JP2015003913A (ja) 2015-01-08
CA2592099A1 (en) 2006-06-29
JP2008525029A (ja) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
DE602005027747D1 (de) Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
EA200700243A1 (ru) Способы лечения гепатита с
EA201290993A1 (ru) Нуклеозидфосфорамидаты
EP2609923A3 (en) Nucleoside Phosphoramidates
MY176918A (en) N- [ (2 ' r) -2' -deoxy-2' -fluoro-2' -methyl-p-phenyl-5' -uridylyl] - l-alanine 1-methylethyl ester and process for its production
DK1554301T3 (da) Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
DK1747023T3 (da) Fremgangsmåder og sammensætninger til formindskelse af HCV-virusgenommængder i en målcelle
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
WO2010047830A3 (en) Agents for hcv treatment
WO2010118367A3 (en) Antiviral pyrimidines
TW200728317A (en) Macrocylic inhibitors of hepatitis C virus
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
ATE475660T1 (de) Antivirale verbindungen
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
ATE541844T1 (de) Antivirale verbindungen
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
WO2007127801A3 (en) Hepatitis c virus infection biomarkers
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
EA200401362A1 (ru) Антивирусная терапия, основанная на противодействии рнк
UA103158C2 (ru) Конъюгат белок-полимер и способ лечения с его помощью
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a
WO2010081095A3 (en) Methods and compositions for inhibiting hepatitis c virus replication